Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure - OPT-CHF


Patients with symptomatic (New York Heart Association [NYHA] class III or IV) systolic (left ventricular ejection fraction [LVEF] ≤40%) congestive heart failure (CHF) were randomized to treatment with oxypurinol (active metabolite of allopurinol) or placebo, in the background of optimal medical therapy. Safety and efficacy were monitored for 24 weeks following randomization.